19:31 , Sep 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Sarcoma Mouse studies suggest combining DIABLO mimetics with an oncolytic vesicular stomatitis virus (VSV) could help treat rhabdomyosarcoma. In an orthotopic xenograft mouse model of the cancer, the DIABLO mimetic LCL161 plus an oncolytic VSV...
20:34 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Debiopharm completes enrollment in Phase I/II of Debio 1143 for SCCHN

Debiopharm Group (Lausanne, Switzerland) completed enrollment of 96 patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck (SCCHN) in the Phase II portion of a double-blind, placebo-controlled, French and Swiss...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

AT-406: Phase II started

Debiopharm began a double-blind Phase II trial of oral Debio 1143 plus carboplatin and paclitaxel. Debiopharm has exclusive, worldwide rights from Ascenta to develop and commercialize Debio 1143 (see BioCentury, Sept. 12, 2011). Ascenta Therapeutics...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Clinical News

AT-406: Phase I data

An open-label, U.S. Phase I trial in 29 AML patients showed that once-daily 100, 200, 300 or 400 mg oral Debio 1143 plus daunorubicin and cytarabine led to complete remission in 13 patients. Of those...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Debio 1143: Phase I started

Debiopharm began a Phase I trial to evaluate Debio 1143 plus carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), platinum-refractory ovarian cancer or basal-like/claudin-low triple negative breast cancer. Debiopharm has exclusive, worldwide...
07:00 , Jul 23, 2012 |  BioCentury  |  Product Development

Debio's dual deal

Debiopharm Group has been stocking up its early stage cancer pipeline with assets it believes have best-in-class potential, the latest being a preclinical dual tyrosine kinase inhibitor from Ascepion Pharmaceuticals Inc. The deal is the...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Company News

Ascenta, Ascentage Pharma Group Corp., Debiopharm deal

Ascenta granted Debiopharm exclusive, worldwide rights to develop and commercialize AT-406 ( Debio 1143). Ascenta will complete two ongoing U.S. Phase I trials with the compound in acute myelogenous leukemia (AML) and in solid...
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); BIRC3 (cIAP2); x-linked inhibitor of apoptosis...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

Ascenta, Ascentage Pharma Group Corp. deal

Ascenta granted Ascentage rights to develop and commercialize AT-101 and AT-406 in China and Taiwan. Ascentage also will have rights to AT-101 for all regions outside the U.S., Canada and Europe. Ascenta will...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

Ascenta preclinical data

AT-406 was active as a single agent in several mouse models of cancer, as well as in breast, lung, pancreatic, prostate and bladder cancer cell lines in vitro. Additionally, AT-406 plus combination tyrosine kinase inhibitors...